ALBO - Albireo Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
28.36
-0.57 (-1.97%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close28.93
Open28.77
Bid20.42 x 800
Ask70.00 x 800
Day's Range28.02 - 29.31
52 Week Range21.25 - 39.87
Volume27,811
Avg. Volume43,746
Market Cap339.466M
Beta (3Y Monthly)1.31
PE Ratio (TTM)N/A
EPS (TTM)-2.73
Earnings DateDec 15, 2016 - Dec 19, 2016
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est63.50
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Albireo Receives FDA Fast Track Designation for A4250

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to lead product candidate A4250, an ileal bile acid transporter inhibitor, which is being developed for the treatment of progressive familial intrahepatic cholestasis (PFIC), a rare and life-threatening liver disease with no approved pharmacologic treatment option. In addition to Fast Track designation, A4250 has received several other special regulatory designations for development in PFIC.

  • GlobeNewswire2 days ago

    Albireo Granted Orphan Drug Designation For Lead Product Candidate A4250 for Treatment of Alagille Syndrome

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to lead product candidate A4250, an ileal bile acid transporter (IBAT) inhibitor, for the treatment of Alagille syndrome, a rare and life-threatening disease that affects the liver and has no approved pharmacologic treatment option. A4250 also holds Orphan Drug Designation from the European Medicines Agency (EMA) for the treatment of Alagille, and Orphan Drug designations from both the FDA and EMA for the treatment of progressive intrahepatic cholestasis (PFIC).

  • GlobeNewswire4 days ago

    Albireo Announces Research on Cholestatic Liver Diseases to be Presented at Major North American Liver Meetings

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that important findings from multiple studies on progressive familial intrahepatic cholestasis (PFIC) and other cholestatic liver diseases will be presented at major upcoming North American liver meetings. Findings from two studies on cholestatic liver diseases will be presented during poster sessions at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2018 Annual Meeting, being held Oct. 24-27, 2018, in Hollywood, Fla. In addition, data from the NAPPED (NAtural course and Prognosis of PFIC and Effect of biliary Diversion) Consortium study evaluating the natural history of PFIC will be presented by an international research team at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, being held Nov. 9-13, 2018, in San Francisco.

  • GlobeNewswire9 days ago

    Albireo Appoints Simon Harford as Chief Financial Officer and Treasurer

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Simon Harford as Chief Financial Officer. Harford will succeed Tom Shea, who is stepping down from the role. “As Albireo moves toward commercialization, we are evolving and strengthening our leadership team,” said Ron Cooper, President and Chief Executive Officer of Albireo.

  • GlobeNewswire24 days ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Pentair plc, Albireo Pharma, Cardlytics, New Oriental Education & Technology Group, State Street, and Axis Capital — New Research Emphasizes Economic Growth

    NEW YORK, Sept. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire25 days ago

    Albireo to Present at Cantor Fitzgerald Global Healthcare Conference

    BOSTON, Sept. 24, 2018-- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Dr. Patrick Horn, Chief Medical Officer, ...

  • GlobeNewswire2 months ago

    Albireo to Present at the H.C. Wainwright Global Investment Conference

    BOSTON, Aug. 29, 2018-- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive ...

  • GlobeNewswire2 months ago

    Albireo to Present at Wedbush PacGrow Healthcare Conference

    BOSTON, Aug. 08, 2018-- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive ...

  • GlobeNewswire2 months ago

    Albireo Reports Second Quarter 2018 Financial Results

    A4250 Phase 3 trial in PFIC underway. A4250 granted rare pediatric disease designation, eligible to apply for priority review voucher. Management to host conference call and webcast today at 8:30 a.m. ...

  • ACCESSWIRE2 months ago

    Albireo Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Albireo Pharma, Inc. (NASDAQ: ALBO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...

  • GlobeNewswire3 months ago

    Albireo to Report Second Quarter 2018 Financial Results, and Host Conference Call and Webcast on August 7, 2018

    BOSTON, Aug. 02, 2018-- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that its second quarter financial results will ...

  • GlobeNewswire3 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Finisar, Albireo Pharma, Corporate Office Properties Trust, Ocean Power Technologies, Depomed, and Potbelly — New Research Emphasizes Economic Growth

    NEW YORK, July 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Finisar ...

  • GlobeNewswire3 months ago

    Albireo Appoints Patrick Horn MD, PhD as Chief Medical Officer

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Dr. Patrick Horn as Chief Medical Officer.  Dr. Horn will succeed Dr. Paresh Soni who will step down from the Chief Medical Officer role but will continue as a consultant to the Company. “Pat brings to Albireo a unique combination of pediatric, orphan and Phase 3-to-approval experience that will be invaluable as we reach a new stage of growth at the Company,” said Ron Cooper, President and Chief Executive Officer of Albireo.

  • ACCESSWIRE5 months ago

    Blog Exposure - Trevena Showcases Data from ATHENA Phase-3 Study at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting

    LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want access to our free research report on Trevena,Inc. (NASDAQ: TRVN), all you need to do is sign up now by clicking thefollowing link www.active-investors.com/registration-sg/?symbol=TRVN as the Company’s latest news hit the wire. OnMay 22, 2018, the Company, which is a biopharmaceutical organization developinginnovative therapies based on breakthrough science to benefit patients and healthcareproviders confronting serious medical conditions, announced that it showcasedtwo presentations at the American Society of Colon and Rectal Surgeons 2018Annual Scientific Meeting. Active-Investors.com is currently working on the researchreport for Albireo Pharma, Inc. (NASDAQ: ALBO), which also belongs to the Healthcaresector as the Company Trevena.

  • ACCESSWIRE5 months ago

    Albireo Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 17, 2018 / Albireo Pharma, Inc. (NASDAQ: ALBO ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 17, 2018 at 8:30 AM Eastern Time. To ...